Fig. 5

GSK805 alleviates intestinal inflammation of NEC mice by inhibiting IL-17A released. a. Scheme of the method of GSK805 treatment. Mice were treated with Mock or GSK805 (10 μg/g) orally. GSK805 was prepared with 1% DMSO in CMC-Na. b. Percentage of initial weight. c. Representative hematoxylin and eosin staining sections of the terminal ileum. d. Histopathological score measuring the severity of tissue lesions in the terminal ileum. e–g. Flow cytometric analysis and quantification of T cell subsets and related cytokines (IL-17A and IL-22) within lamina propria in small intestine. h–j. Flow cytometric analysis and quantification of ILC3 and related cytokines (IL-17A and IL-22). Four independent experiments were performed, n = 4–5 per group. Data were shown as mean values ± SD. Statistical analyses were performed with Student’s two-tailed unpaired t-test. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Scale bars represent 50 μm